These data indicate that CCT2 could act as a molecular marker to successfully target those cells that acquire an invasive migratory phenotype, which is a hallmark of metastatic cancer, without the need to first identify genetic markers or transcriptional programs that, to date, are not fully characterized in neuroblastoma. The gene discussed is CCT2; the disease is metastatic malignant neoplasm.